Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Fry

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Plos One|October 17, 2018
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjectsMatthew W McClure, Elina Berliba, Tengiz Tsertsvadze, et al.
Nature Reviews. Gastroenterology & Hepatology|October 7, 2022
Nomenclature of HBV core protein-targeting antiviralsFabien Zoulim, Adam Zlotnick, Stephanie Buchholz, et al.
Gastroenterology|April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic InfectionFabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Hepatology (Baltimore, Md.)|December 3, 2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsEugene R Schiff, Ching-Lung Lai, Stefanos Hadziyannis, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Plos One|October 17, 2018
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjectsMatthew W McClure, Elina Berliba, Tengiz Tsertsvadze, et al.
Nature Reviews. Gastroenterology & Hepatology|October 7, 2022
Nomenclature of HBV core protein-targeting antiviralsFabien Zoulim, Adam Zlotnick, Stephanie Buchholz, et al.
Gastroenterology|April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic InfectionFabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Hepatology (Baltimore, Md.)|December 3, 2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsEugene R Schiff, Ching-Lung Lai, Stefanos Hadziyannis, et al.
Pageof 4